Twilio believes that when people have access to the information and resources they need, they can take action to improve their outcomes and long-term wellbeing. That’s why the company worked to drive better outcomes across the vaccine lifecycle.

Twilio contributed $10 million to Gavi, the Vaccine Alliance that supports COVAX, an initiative to provide vaccines to low and middle-income countries. Twilio grantees and customers are also using on-the-ground expertise and technology to solve complex distribution challenges and the company is also partnering with organizations to build vaccine understanding and confidence. Finally, many organizations are using Twilio to connect to people directly and increase vaccination rates by communicating availability, booking appointments and delivering reminders about subsequent shots. 

“For me, Twilio has been THE stand-out technology company that has really put action behind words to support vaccine equity. The company has not only led through substantive funding but equally through the team’s energy, creativity and sheer dedication to get a product to market that actually aims to change things for the future.”

You can read more about Twilio’s work here.

IBM is in a unique position to uncover new insights to address the opioid epidemic. Its Science for Good program focuses on analyzing the relationship between factors surrounding an initial opioid prescription and a subsequent diagnosis of addiction. The goal is to identify causal (and not merely correlated) factors that lead to an addiction diagnosis. 

IBM’s work represents the beginning of a long and potentially far-reaching mission to make inferences about undiagnosed individuals in order to offer guidelines on opioid prescriptions.

“Overall, our vision is to draw upon the richness of IBM’s claims and other healthcare data to deliver insights tailored to the needs of different stakeholders. With an epidemic of this magnitude, such joint efforts are clearly needed.”

You can read more about IBM’s work here.